{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:39Z","timestamp":1787238159816,"version":"build-2736575974"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"\n Importance<\/jats:title>\n Change from baseline score on the validated Psoriasis Symptoms and Signs Diary (PSSD) is a widely used, patient-reported end point in clinical trials for psoriasis. Meaningful score change thresholds anchored to patient-reported assessments have not been established in a clinical trial setting.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate meaningful within-patient score change thresholds for the PSSD using data from the phase 3 Program to Evaluate the Efficacy and Safety of Deucravacitinib, a Selective TYK2 Inhibitor (POETYK), PSO-1 clinical trial, which compared the efficacy and safety of deucravacitinib vs placebo and apremilast among adults with moderate to severe plaque psoriasis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this predefined analysis using data from the POETYK PSO-1 multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial, conducted from August 7, 2018, to September 2, 2020, 666 adults with moderate to severe plaque psoriasis completed the PSSD daily throughout the trial. Meaningful change thresholds were derived by anchoring mean PSSD score change from baseline to week 16 to category improvements on the Patient Global Impression of Change (PGI-C) and the Patient Global Impression of Severity (PGI-S).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Deucravacitinib, 6 mg, once daily; placebo; or apremilast, 30 mg, twice daily.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The main outcome was score change from baseline to week 16 on the PSSD, anchored to the PGI-C and PGI-S.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The trial included 666 patients (mean [SD] age, 46.1 [13.4] years; 453 men [68.0%]). Three thresholds were identified using an analysis set of 609 patients. Score improvement of at least 15 points from baseline reflected meaningful within-patient change anchored to the PGI-C. Score improvements of 25 points were supported by both the PGI-C and the PGI-S, while a 30-point score change identified patients with greater improvements in their psoriasis symptoms and signs.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This analysis suggests that PSSD score improvements of 15, 25, or 30 points represent increasing improvements in disease burden that are meaningful to patients with psoriasis.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.5058","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:02:41Z","timestamp":1703070161000},"page":"204","source":"Crossref","is-referenced-by-count":5,"title":["Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary"],"prefix":"10.1001","volume":"160","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[{"name":"Probity Medical Research, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University, New Haven, Connecticut"},{"name":"Central Connecticut Dermatology, Cromwell"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Becker","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhong","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Solutions, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan P.","family":"Pham","sequence":"additional","affiliation":[{"name":"Clinical Outcomes Solutions, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kisa","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Napoli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"dbr230022r1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/09546634.2015.1114567","article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary.","volume":"27","author":"Mathias","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"dbr230022r2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09546634.2017.1364694","article-title":"Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase 3 clinical trial.","volume":"30","author":"Armstrong","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"dbr230022r3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdds.2015.07.004","article-title":"Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary.","volume":"20","author":"Feldman","year":"2016","journal-title":"J Dermatol Dermatol Surg"},{"key":"dbr230022r6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jad.2020.11.066","article-title":"Meaningful change in depression symptoms assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-\u00c5sberg Depression Rating Scale (MADRS) among patients with treatment resistant depression in two, randomized, double-blind, active-controlled trials of esketamine nasal spray combined with a new oral antidepressant.","volume":"281","author":"Hudgens","year":"2021","journal-title":"J Affect Disord"},{"key":"dbr230022r7","doi-asserted-by":"publisher","journal-title":"J Am Acad Dermatol","DOI":"10.1016\/j.jaad.2022.07.002"},{"issue":"20","key":"dbr230022r8","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"dbr230022r9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jdv.2018.32.issue-9","article-title":"Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.","volume":"32","author":"Papp","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"dbr230022r10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores.","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"key":"dbr230022r11","doi-asserted-by":"publisher","first-page":"m1714","DOI":"10.1136\/bmj.m1714","article-title":"Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study.","volume":"369","author":"Devji","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"dbr230022r12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","article-title":"Defining clinically meaningful change in health-related quality of life.","volume":"56","author":"Crosby","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"dbr230022r13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12955-016-0427-5","article-title":"Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients.","volume":"14","author":"Nixon","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"dbr230022r14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2522\/ptj.20130162","article-title":"Patient global ratings of change did not adequately reflect change over time: a clinical cohort study.","volume":"94","author":"Schmitt","year":"2014","journal-title":"Phys Ther"},{"key":"dbr230022r15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2021.12.024","article-title":"Present state bias in transition ratings was accurately estimated in simulated and real data.","volume":"143","author":"Terluin","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"dbr230022r16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","article-title":"Interpreting change in scores on patient-reported outcome instruments.","volume":"50","author":"Coon","year":"2016","journal-title":"Ther Innov Regul Sci"},{"key":"dbr230022r4","unstructured":"U.S. Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims: guidance for industry. December 2009. Accessed June 14, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims"},{"key":"dbr230022r5","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. April 2023. Accessed September 7, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2812733\/jamadermatology_papp_2023_br_230022_1707346967.48895.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:02:14Z","timestamp":1708513334000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2812733"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5058","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}